Australian-based CRO Novotech is expanding into four new Asian markets with the establishment of a management hub in Kuala Lumpur. The hub will cover Novotech’s presence in Singapore, Thailand and the Philippines, adding to a joint venture presence in India and an office in Korea.

“A sizeable patient population, transparent regulatory environment, time zone compatibility with the Australian headquarters and government and clinical sector support for research all make the region very attractive,” CEO Alek Safarian. Safarian said growth predictions for outsourced clinical trials in Asia are strong and the company expects to generate more than 50% of its revenues from outside Australia in three to five years.

By Nick Lush

http://www.trialsinfocus.com/